-
RYTM Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Rhythm Pharmaceuticals (RYTM)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 47.98 mm | 47.98 mm | 47.98 mm | 47.98 mm | 47.98 mm | 47.98 mm |
Cash burn (monthly) | 38.05 mm | 1.41 mm | 14.66 mm | 22.25 mm | 8.40 mm | 10.37 mm |
Cash used (since last report) | 162.05 mm | 6.01 mm | 62.45 mm | 94.76 mm | 35.80 mm | 44.16 mm |
Cash remaining | -114.07 mm | 41.97 mm | -14.46 mm | -46.77 mm | 12.19 mm | 3.82 mm |
Runway (months of cash) | -3.0 | 29.7 | -1.0 | -2.1 | 1.4 | 0.4 |
13F holders | Current |
---|---|
Total holders | 183 |
Opened positions | 32 |
Closed positions | 20 |
Increased positions | 60 |
Reduced positions | 54 |
13F shares | Current |
---|---|
Total value | 3.46 tn |
Total shares | 74.25 mm |
Total puts | 78.60 k |
Total calls | 833.60 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Primecap Management | 7.22 mm | $378.09 bn |
BlackRock | 6.89 mm | $360.93 bn |
Baker Bros. Advisors | 6.40 mm | $335.21 bn |
Ra Capital Management | 6.08 mm | $318.76 bn |
GS The Goldman Sachs Group, Inc. | 3.88 mm | $203.26 bn |
Perceptive Advisors | 3.56 mm | $186.52 bn |
Vanguard | 3.45 mm | $180.64 bn |
New Enterprise Associates 13 | 2.91 mm | $70.83 mm |
NEA Management | 2.91 mm | $152.45 bn |
Frazier Life Sciences Management | 2.42 mm | $126.62 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Feb 25 | Pamela J. Cramer | Common Stock | Sell | Dispose S | No | Yes | 59.43 | 902 | 53.61 k | 15,248 |
4 Feb 25 | Jennifer Chien | Common Stock | Sell | Dispose S | No | Yes | 59.43 | 1,447 | 86.00 k | 4,038 |
4 Feb 25 | Meeker David P | Common Stock | Sell | Dispose S | No | Yes | 59.43 | 4,278 | 254.24 k | 189,927 |
4 Feb 25 | Joseph Shulman | Common Stock | Sell | Dispose S | No | Yes | 59.43 | 1,281 | 76.13 k | 2,657 |
4 Feb 25 | Smith Hunter C | Common Stock | Sell | Dispose S | No | Yes | 59.43 | 1,678 | 99.72 k | 101,186 |
1 Feb 25 | Pamela J. Cramer | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,650 | 0.00 | 16,150 |
1 Feb 25 | Pamela J. Cramer | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,650 | 0.00 | 5,300 |
1 Feb 25 | Jennifer Chien | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,513 | 0.00 | 5,485 |
1 Feb 25 | Jennifer Chien | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,513 | 0.00 | 9,024 |
1 Feb 25 | Meeker David P | Common Stock | Option exercise | Acquire M | No | No | 0 | 14,125 | 0.00 | 194,205 |